Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Kintor Pharmaceutical Ltd ( (HK:9939) ) is now available.
Kintor Pharmaceutical Limited has postponed its scheduled board meeting, originally set for March 26, 2026, to March 30, 2026, due to the directors’ timetable constraints. The meeting’s agenda includes reviewing and approving the company’s annual results for the year ended December 31, 2025, and the delay may slightly shift the timing of the results’ publication but does not indicate any change in their expected scope or content.
The rescheduling highlights routine governance and logistical considerations rather than signaling operational or financial distress. Investors and other stakeholders may experience a brief extension in the disclosure timeline, but the company maintains its commitment to completing its annual reporting process under the oversight of its current board and management team.
The most recent analyst rating on (HK:9939) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Kintor Pharmaceutical Ltd stock, see the HK:9939 Stock Forecast page.
More about Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited is a Hong Kong-listed biopharmaceutical company incorporated in the Cayman Islands. The company focuses on developing and commercializing innovative pharmaceutical products, operating through a board structure that includes executive, non-executive and independent non-executive directors overseeing its strategic and regulatory responsibilities.
Average Trading Volume: 4,063,102
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.47B
Find detailed analytics on 9939 stock on TipRanks’ Stock Analysis page.